07.17.17
Ionis Pharmaceuticals has earned a $10 million milestone payment from Biogen associated with the validation of an undisclosed neurological disease target. Ionis and Biogen have a broad strategic collaboration to develop drugs to treat patients with neurological disorders. Ionis will continue to evaluate this newest target with the goal of advancing this program into development.
"We continue to make substantial progress in validating new targets and developing new drugs for neurological diseases using our antisense technology. Spinraza, the first drug to come out of our neurology collaboration with Biogen, exemplifies the potential of our antisense technology in the neurological disease space. To date, our collaboration with Biogen has generated a combined total of nearly $650 million," said B. Lynne Parshall, chief operating officer, Ionis Pharmaceuticals. "As we continue to advance our neurological disease pipeline, we look forward to bringing additional important medicines to patients suffering from neurodegenerative diseases."
"We continue to make substantial progress in validating new targets and developing new drugs for neurological diseases using our antisense technology. Spinraza, the first drug to come out of our neurology collaboration with Biogen, exemplifies the potential of our antisense technology in the neurological disease space. To date, our collaboration with Biogen has generated a combined total of nearly $650 million," said B. Lynne Parshall, chief operating officer, Ionis Pharmaceuticals. "As we continue to advance our neurological disease pipeline, we look forward to bringing additional important medicines to patients suffering from neurodegenerative diseases."